Immune control of HIV-1 after early treatment of acute infection

Nature

Volumn 407, Issue 6803, 2000, Pages 523-526

  Rosenberg, Eric S ^a   Altfeld, Marcus ^a   Poon, Samuel H ^a   Phillips, Mary N ^a   Wilkes, Barbara M ^a   Eldridge, Robert L ^a   Robbins, Gregory K ^a   D'Aqulla, Richard T ^a   Goulder, Philip J R ^a   Walker, Bruce D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NELFINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

ACUTE DISEASE; ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV-1; HUMAN; MALE; PILOT PROJECTS; RNA, VIRAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, HELPER-INDUCER; VIRAL LOAD; VIREMIA;

EID: 0034727073     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/35035103     Document Type: Article

References (29)

1. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68, 8056-8063 (1994).
2. + T-cell-deficient mice. J. Virol. 68, 4700-4704 (1994).
3. + T cell responses associated with control of viremia. Science 278, 1447-1450 (1997).
4. + T lymphocytes. Proc. Natl Acad. Sci. USA 97, 3382-3387 (2000).
5. Malhotra, U. et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type I infection. J. Infect. Dis. 181, 121-131 (2000).
6. Kalams, S. A. & Walker, B. D. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188, 2199-2204 (1998).
7. von Herrath, M. G., Yokohama, M., Dockter, J., Oldstone, M. B. & Whitton, J. L. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70, 1072-1079 (1996).
8. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998).
9. Kalams, S. A. et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J. Virol. 73, 6715-6720 (1999).
10. Gerlach, J. T. et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T- cell response in acute hepatitis C. Gastroenterology 117, 933-941 (1999).
11. Lechner, F. et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191, 1499-1512 (2000).
12. Lisziewicz, J. et al. Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med. 340, 1683-1684 (1999).
13. Ortiz, G. M. et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J. Clin. Invest. 104, R13-R18 (1999).
14. Kahn, J. O. & Walker, B. D. Acute human immunodeficiency virus type 1 infection. N. Engl. J. Med. 339, 33-39 (1998).
15. Lori, F. et al. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J. Infect. Dis. 180, 1827-1832 (1999).
16. Carpenter, C. C. et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the international AIDS Society/USA panel. J. Am. Med. Assoc. 277, 1962-1969 (1997).
17. Lyles, R. H. et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J. Infect. Dis. 181, 872-880 (2000).
18. + T cells with a predominant V beta usage during the primary immune response to HIV. Nature 370, 463-467 (1994).
19. + T cell homeostasis and function in advanced HIV disease. Science 277, 112-116 (1997).
20. Evans, D. T. et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nature Med. 5, 1270-1276 (1999).
21. Dhodapkar, M. V. et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104, 173-180 (1999).
22. Davey, R. T. Jr et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl Acad. Sci. USA 96, 15109-15114 (1999).
23. Janssen, R. S. et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. J. Am. Med. Assoc. 280, 42-48 (1998).
24. Little, S. J. et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. J. Am. Med. Assoc. 282, 1142-1149 (1999).
25. Brander, C. & Walker, B. D. in Molecular Immunology Data Base (eds Korber, B. T. et al.) IV-50-IV-60 (Los Alamos National Laboratory, Los Alamos, New Mexico, 1997).
26. Goulder, P. J. et al. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. J. Virol. 74, 5679-5690 (2000).
27. Walker, B. D. et al. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 86, 9514-9518 (1989).
28. Martinez-Picado, J., Sutton, L., De Pasquale, M. P., Savara, A. V. & D'Aquila, R. T. Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing. J. Clin. Microbiol. 37, 2943-2951 (1999).
29. Kalams, S. A. et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T- lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 73, 6721-6728 (1999).